Adial Pharmaceuticals, Inc.ADIL
Price (close)
$4.22
Market cap
$11.1M
P/E
—
Revenue (TTM)
—
Net income
-$57.8M
Dividend yield
—
1-year total return
-48.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What Adial Pharmaceuticals, Inc. does.
are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction
and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol
use disorder (“AUD”). AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$10.9M | -$19.4M | -$12.7M | -$5.1M | -$13.2M | -$8.0M |
| Free cash flow | — | -$12.0M | — | — | — | — |
More on ADIL.
- Adial Pharmaceuticals, Inc. summary
- Adial Pharmaceuticals, Inc. financial statements
- Adial Pharmaceuticals, Inc. key metrics
- Adial Pharmaceuticals, Inc. health scores and style box
- Adial Pharmaceuticals, Inc. earnings
- Adial Pharmaceuticals, Inc. dividends
- Adial Pharmaceuticals, Inc. valuation
- Adial Pharmaceuticals, Inc. ownership and insiders
- Adial Pharmaceuticals, Inc. peers
Figures from Adial Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.